SCHEMBL9942869

SCHEMBL9942869

Cc1ccc(S(=O)(=O)OCC23CCC(N)(CC2)c2nc(C(=O)NCc4ccc(F)c(C)c4)c(O)c(=O)n2C3)cc1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.35
KCNH2 Q12809 1/20 0.35
MMP10 P09238 2/20 0.33
MMP8 P22894 2/20 0.33
NAMPT P43490 3/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RECQL P46063 1/20 0.31
KLKB1 P03952 1/20 0.31
KLK1 P06870 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9942971 0.91 KCNH2 (0.35) MMP13KCNH2MMP10MMP8NAMPT
SCHEMBL9905172 0.89 KCNH2 (0.35) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9904915 0.87 CYP2C9 (0.38) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9904934 0.87 MMP13 (0.36) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9901046 0.87 CYP2C9 (0.37) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9942882 0.85 RORC (0.32) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9943066 0.85 MMP13 (0.41) MMP13KCNH2MMP10MMP8CYP2C9
SCHEMBL9942931 0.84 KCNH2 (0.34) MMP13KCNH2MMP10MMP8NAMPT
SCHEMBL9942948 0.82 KCNH2 (0.43) KCNH2CYP2C9PKMTDP1TP53
SCHEMBL9942907 0.79 CYP2C9 (0.46) KCNH2CYP2C9PKMTDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-8835411-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-16 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
US-20120309698-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 US disclosed
WO-2012078834-A1 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309698-A1 HIV Integrase Inhibitors DNTT, POLB, UNG MMP13 4137/4885KCNH2 3969/4885MMP10 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.